Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Efficacy and Safety of Subcutaneous Abatacept in the Prevention of Acute Graft-versus-host Disease After Haplo-identical Donor Hematopoietic Cell Transplantation

Next Previous
X
Search
Trial Profile

The Efficacy and Safety of Subcutaneous Abatacept in the Prevention of Acute Graft-versus-host Disease After Haplo-identical Donor Hematopoietic Cell Transplantation

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abatacept (Primary) ; Antithymocyte globulin; Busulfan; Ciclosporin; Cyclophosphamide; Methotrexate; Mycophenolate mofetil
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use

    • Most Recent Events

    • 17 Dec 2022 According to ClinicalTrials.gov record, protocol has been amended as treatment arm changed from 2 to 1
    • 17 Dec 2022 Planned End Date changed from 30 Dec 2022 to 30 Dec 2023.
    • 17 Dec 2022 Planned primary completion date changed from 30 Apr 2022 to 30 Jun 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top